David W. Gibbs filed a Form 3 Initial Statement of Beneficial Ownership with the SEC on October 26, 2026, disclosing his status as a newly appointed director of Amgen Inc., traded on NASDAQ:AMGN.

Key Highlights

  • Reporting person: David W. Gibbs, identified as a Director of Amgen Inc.
  • Event date: The date of event requiring the statement is October 26, 2026.
  • No securities held: The filing states explicitly, "No securities are beneficially owned."
  • Scope: Both Table I (non-derivative securities) and Table II (derivative securities) are blank, with no entries reported.
  • Filing type: Filed as an individual reporting person, not as part of a joint or group filing.

Gibbs Reports Zero Beneficial Ownership Upon Joining Amgen Board

According to the filing, David W. Gibbs submitted a Form 3 to the SEC on October 26, 2026, in connection with becoming a Director of Amgen Inc. (NASDAQ:AMGN). The Form 3 serves as an initial statement of beneficial ownership required under Section 16(a) of the Securities Exchange Act of 1934 for officers, directors, and certain beneficial owners upon first becoming subject to reporting obligations.

The filing discloses that Gibbs holds no beneficial ownership of any Amgen securities, either directly or indirectly. Table I, which covers non-derivative securities such as common stock, contains no entries. Table II, covering derivative securities such as options, warrants, or convertible instruments, is also blank. The filing's explanation of responses states plainly: "No securities are beneficially owned."

Gibbs's address is listed in the filing as One Amgen Center Drive, Thousand Oaks, California 91320-1799. The filing was signed by David W. Gibbs and is dated October 26, 2026. No amendments to a prior Form 3 are indicated, confirming this is an original initial statement.

What Was Disclosed

David W. Gibbs filed an initial beneficial ownership statement as a new Director of Amgen Inc., reporting no holdings in any class of the company's securities, including both non-derivative and derivative instruments, as of October 26, 2026.